Full Year 2025 Fresenius SE & Co KGaA Earnings Call Transcript
Key Points
- Fresenius SE & Co KGaA (FSNUY) delivered strong organic growth with a 7% increase in revenue and 6% EBIT growth at constant currency for 2025.
- The company achieved a double-digit growth in core EPS for the second consecutive year, demonstrating strong operating leverage.
- Fresenius SE & Co KGaA's balance sheet is significantly stronger, with a net debt to EBITDA ratio of 2.7, providing enhanced strategic flexibility.
- The company proposed a 5% increase in its dividend to EUR 1.05 per share, reflecting its improving financial strength.
- Fresenius SE & Co KGaA's biopharma segment continues to show strong momentum, with a clear path to double revenue by 2030.
- The macroeconomic environment remains volatile, with uncertainties such as the US Supreme Court ruling on tariffs impacting the company's outlook.
- Helios Germany is not yet delivering in line with expectations, and closing this gap is a management priority for 2026.
- The company faces competitive pressures in its biosimilars business, which could impact market share and pricing.
- There are concerns about the sustainability of growth in the biopharma segment due to potential increased competition.
- Corporate costs are expected to increase significantly, which could erode margin expansions at Helios and Kabi.
Good afternoon and welcome to the conference call of Fresenius Investor Relations, which is now starting. May I hand you over to Nick Stone, Head of Investor Relations.
Thank you Valentina.Hello everyone, good morning, good afternoon, wherever you are. Welcome to our full year and Q4 2025 earnings call and webcast. Presentation was emailed to our distribution list earlier today and is available on freenius.com.
On slide 2 of the present you'll find the usual Safe Harbor statements unless stated otherwise, we'll comment on our performance using constant exchange rates or [CER]. Today I'm pleased to welcome Michael and Sara who will present another competitive performance, followed by an overview of the full year '26 guidance and the underlying components.
As usual, the call will last approximately one hour with the presentation taking between 35 to 40 minutes and remaining time for your questions. To give everyone the chance to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
